{"id":968014,"date":"2026-05-28T08:15:58","date_gmt":"2026-05-28T12:15:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/"},"modified":"2026-05-28T08:15:58","modified_gmt":"2026-05-28T12:15:58","slug":"eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/","title":{"rendered":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference"},"content":{"rendered":"
\n

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere\u2122 technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company\u2019s management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026.<\/p>\n

\n Jefferies Global Healthcare Conference<\/strong>
\n
\n 1×1 Meetings:<\/strong> June 3rd<\/sup> and 4th<\/sup>
Presentation Date & Time: <\/strong>June 3rd<\/sup>, 2026, at 5:30PM \u2013 6:00PM ET
Location: <\/strong>New York, NY
Webcast registration link: <\/strong>https:\/\/event.summitcast.com\/view\/NgCqua4VVQjq9ibVWHVWca\/8dAzVtF9jmoLFUYwXokBzq<\/a><\/p>\n

If you are interested in meeting with the Eupraxia team during the conference, please contact your Jefferies representative.<\/p>\n

\n About Eupraxia Pharmaceuticals Inc.<\/strong>\n <\/p>\n

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere\u2122, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere\u2122 technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia’s Diffusphere\u2122 technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.<\/p>\n

Eupraxia’s EP-104GI is currently in a Phase 1b\/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com<\/a>.<\/p>\n

\n For investor and media inquiries, please contact:<\/strong>\n <\/p>\n

James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com<\/a><\/p>\n

or<\/p>\n

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com<\/a><\/p>\n

SOURCE Eupraxia Pharmaceuticals Inc.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere\u2122 technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company\u2019s management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. Jefferies Global Healthcare Conference 1×1 Meetings: June 3rd and 4thPresentation Date & Time: June 3rd, 2026, at 5:30PM \u2013 6:00PM ETLocation: New York, NYWebcast registration link: https:\/\/event.summitcast.com\/view\/NgCqua4VVQjq9ibVWHVWca\/8dAzVtF9jmoLFUYwXokBzq If you are interested in meeting with the Eupraxia team during the conference, please contact your Jefferies representative. About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development … <\/p>\n

Continue reading “Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968014","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere\u2122 technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company\u2019s management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. Jefferies Global Healthcare Conference 1×1 Meetings: June 3rd and 4thPresentation Date & Time: June 3rd, 2026, at 5:30PM \u2013 6:00PM ETLocation: New York, NYWebcast registration link: https:\/\/event.summitcast.com\/view\/NgCqua4VVQjq9ibVWHVWca\/8dAzVtF9jmoLFUYwXokBzq If you are interested in meeting with the Eupraxia team during the conference, please contact your Jefferies representative. About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development … Continue reading "Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T12:15:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference\",\"datePublished\":\"2026-05-28T12:15:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/\"},\"wordCount\":466,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/\",\"name\":\"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=\",\"datePublished\":\"2026-05-28T12:15:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk","og_description":"VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere\u2122 technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company\u2019s management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. Jefferies Global Healthcare Conference 1×1 Meetings: June 3rd and 4thPresentation Date & Time: June 3rd, 2026, at 5:30PM \u2013 6:00PM ETLocation: New York, NYWebcast registration link: https:\/\/event.summitcast.com\/view\/NgCqua4VVQjq9ibVWHVWca\/8dAzVtF9jmoLFUYwXokBzq If you are interested in meeting with the Eupraxia team during the conference, please contact your Jefferies representative. About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development … Continue reading \"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-28T12:15:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference","datePublished":"2026-05-28T12:15:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/"},"wordCount":466,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/","name":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=","datePublished":"2026-05-28T12:15:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzkxNyM3NjI1MTI0IzIyNTQ0NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eupraxia-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968014"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968014\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}